PRESS RELEASE – Börje Haraldsson appointed CEO of Oncorena AB

LUND, SWEDEN, June 20, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that… Read More

Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska…

LUND, SWEDEN, February 1, 2022 – Oncorena today announced the initiation of the Phase I-II clinical trial of the first-in-class compound orellanine in patients with advanced kidney… Read More

Oncorena Secures Financing of Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer

LUND, SWEDEN, December 23, 2021 – Oncorena, developing a potential breakthrough therapy for advanced renal cancer, receives a capital injection of MSEK 66 from one of the… Read More